INTEGRATE-neo: a pipeline for personalized gene fusion neoantigen discovery
- PMID: 27797777
- PMCID: PMC5408800
- DOI: 10.1093/bioinformatics/btw674
INTEGRATE-neo: a pipeline for personalized gene fusion neoantigen discovery
Abstract
Motivation: While high-throughput sequencing (HTS) has been used successfully to discover tumor-specific mutant peptides (neoantigens) from somatic missense mutations, the field currently lacks a method for identifying which gene fusions may generate neoantigens.
Results: We demonstrate the application of our gene fusion neoantigen discovery pipeline, called INTEGRATE-Neo, by identifying gene fusions in prostate cancers that may produce neoantigens.
Availability and implementation: INTEGRATE-Neo is implemented in C ++ and Python. Full source code and installation instructions are freely available from https://github.com/ChrisMaherLab/INTEGRATE-Neo .
Contact: christophermaher@wustl.edu.
Supplementary information: Supplementary data are available at Bioinformatics online.
© The Author 2016. Published by Oxford University Press.
Figures
Similar articles
-
ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.BMC Med Genomics. 2020 Apr 3;13(Suppl 5):52. doi: 10.1186/s12920-020-0683-4. BMC Med Genomics. 2020. PMID: 32241270 Free PMC article.
-
CloudNeo: a cloud pipeline for identifying patient-specific tumor neoantigens.Bioinformatics. 2017 Oct 1;33(19):3110-3112. doi: 10.1093/bioinformatics/btx375. Bioinformatics. 2017. PMID: 28605406 Free PMC article.
-
ScanNeo2: a comprehensive workflow for neoantigen detection and immunogenicity prediction from diverse genomic and transcriptomic alterations.Bioinformatics. 2023 Nov 1;39(11):btad659. doi: 10.1093/bioinformatics/btad659. Bioinformatics. 2023. PMID: 37882750 Free PMC article.
-
Harnessing gene fusion-derived neoantigens for 'cold' breast and prostate tumor immunotherapy.Immunotherapy. 2022 Oct;14(14):1165-1179. doi: 10.2217/imt-2022-0081. Epub 2022 Aug 31. Immunotherapy. 2022. PMID: 36043380 Review.
-
Alternative tumour-specific antigens.Nat Rev Cancer. 2019 Aug;19(8):465-478. doi: 10.1038/s41568-019-0162-4. Epub 2019 Jul 5. Nat Rev Cancer. 2019. PMID: 31278396 Free PMC article. Review.
Cited by
-
Neoantigens: promising targets for cancer therapy.Signal Transduct Target Ther. 2023 Jan 6;8(1):9. doi: 10.1038/s41392-022-01270-x. Signal Transduct Target Ther. 2023. PMID: 36604431 Free PMC article. Review.
-
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges.J Immunother Cancer. 2019 Jul 15;7(1):183. doi: 10.1186/s40425-019-0647-4. J Immunother Cancer. 2019. PMID: 31307554 Free PMC article. Review.
-
Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations.Curr Oncol. 2024 Aug 23;31(9):4855-4884. doi: 10.3390/curroncol31090361. Curr Oncol. 2024. PMID: 39329989 Free PMC article. Review.
-
Identifying Strong Neoantigen MHC-I/II Binding Candidates for Targeted Immunotherapy with SINE.Int J Mol Sci. 2024 Dec 29;26(1):205. doi: 10.3390/ijms26010205. Int J Mol Sci. 2024. PMID: 39796063 Free PMC article.
-
DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity.Front Immunol. 2019 Nov 1;10:2559. doi: 10.3389/fimmu.2019.02559. eCollection 2019. Front Immunol. 2019. PMID: 31736974 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases